Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade C 1.04 -3.70% -0.04
ALIM closed down 3.7 percent on Friday, September 21, 2018, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical ALIM trend table...

Date Alert Name Type % Chg
Sep 21 Fell Below 200 DMA Bearish 0.00%
Sep 21 Fell Below 20 DMA Bearish 0.00%
Sep 21 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Sep 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 20 MACD Bearish Signal Line Cross Bearish -3.70%
Sep 20 1,2,3 Pullback Bullish Bullish Swing Setup -3.70%
Sep 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.70%
Sep 20 Narrow Range Bar Range Contraction -3.70%
Sep 20 Inside Day Range Contraction -3.70%
Sep 19 200 DMA Support Bullish -2.80%

Older signals for ALIM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Is ALIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.46
52 Week Low 0.74
Average Volume 154,139
200-Day Moving Average 1.0659
50-Day Moving Average 1.0163
20-Day Moving Average 1.0642
10-Day Moving Average 1.097
Average True Range 0.0642
ADX 35.27
+DI 19.9599
-DI 13.0174
Chandelier Exit (Long, 3 ATRs ) 0.9874
Chandelier Exit (Short, 3 ATRs ) 1.0826
Upper Bollinger Band 1.1566
Lower Bollinger Band 0.9718
Percent B (%b) 0.37
BandWidth 17.365157
MACD Line 0.0281
MACD Signal Line 0.0333
MACD Histogram -0.0052
Fundamentals Value
Market Cap 71.81 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -2.67
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.13
Resistance 3 (R3) 1.14 1.12 1.12
Resistance 2 (R2) 1.12 1.10 1.12 1.11
Resistance 1 (R1) 1.08 1.08 1.07 1.07 1.10
Pivot Point 1.06 1.06 1.06 1.06 1.06
Support 1 (S1) 1.02 1.04 1.01 1.01 0.98
Support 2 (S2) 1.00 1.02 1.00 0.97
Support 3 (S3) 0.96 1.00 0.97
Support 4 (S4) 0.95